These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 7992254)
1. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation. Elgue G; Sanchez J; Egberg N; Olsson P Thromb Res; 1994 Sep; 75(5):539-49. PubMed ID: 7992254 [TBL] [Abstract][Full Text] [Related]
2. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450 [TBL] [Abstract][Full Text] [Related]
3. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization. Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548 [TBL] [Abstract][Full Text] [Related]
4. Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery. Swedenborg J; Nydahl S; Egberg N Eur J Vasc Endovasc Surg; 1996 Jan; 11(1):59-64. PubMed ID: 8564488 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. Meddahi S; Bara L; Fessi H; Samama MM Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099 [TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin). Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120 [TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. Buyue Y; Misenheimer TM; Sheehan JP J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III. Baruch D; Lindhout T; Wagenvoord R; Hemker HC Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193 [TBL] [Abstract][Full Text] [Related]
9. Influence of different anticoagulant agents on fibrinopeptide a generation. Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437 [TBL] [Abstract][Full Text] [Related]
11. Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo. Hérault JP; Cappelle M; Bernat A; Millet L; Bono F; Schaeffer P; Herbert JM J Thromb Haemost; 2003 Sep; 1(9):1959-65. PubMed ID: 12941037 [TBL] [Abstract][Full Text] [Related]
12. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency. Herren T; Straub PW; Haeberli A Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646 [TBL] [Abstract][Full Text] [Related]
13. The course of disseminated intravascular coagulation is predicted by changes in thrombin-antithrombin III complex levels--is there any difference between treatment with standard heparin or low-molecular-weight heparin? Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T Blood Coagul Fibrinolysis; 1991 Oct; 2(5):623-7. PubMed ID: 1664251 [TBL] [Abstract][Full Text] [Related]
14. From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation. Spadarella G; Di Minno A; Donati MB; Mormile M; Ventre I; Di Minno G Blood Rev; 2020 Jan; 39():100613. PubMed ID: 31471127 [TBL] [Abstract][Full Text] [Related]
15. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin. Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069 [TBL] [Abstract][Full Text] [Related]
16. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751 [TBL] [Abstract][Full Text] [Related]
17. Covalent antithrombin-heparin effect on thrombin-thrombomodulin and activated protein C reaction with factor V/Va. Van Walderveen MC; Berry LR; Atkinson HM; Chan AK Thromb Haemost; 2010 May; 103(5):910-9. PubMed ID: 20216984 [TBL] [Abstract][Full Text] [Related]
18. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929 [TBL] [Abstract][Full Text] [Related]
19. Involvement of the extrinsic pathway in the activities of low molecular weight heparins. Norrheim L; Abildgaard U; Larsen ML; Lindahl AK Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967 [TBL] [Abstract][Full Text] [Related]
20. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Elgue G; Blombäck M; Olsson P; Riesenfeld J Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]